ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,770.20
0.55%
US Tech 100
19,636.04
0.55%
다우존스 지수
42,801.72
0.52%
Bitcoin
82,235.93
-4.55%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Carmell Corporation (CTCX)

  7. Carmell Corporation (CTCX) 뉴스

Carmell Corporation

Carmell Corporation (CTCX)

NASDAQ
0.1973
0.0027
(1.39%)
마감 10 3월 5:00AM
15분 지연
0.1973
0.00
(0.00%)
시간외 거래: 9:56AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

CTCX 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
06 1월 2024
CTCX (1.39%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 12월 2023
CTCX (1.39%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 12월 2023
CTCX (1.39%)

CTCX Discussion

게시물 보기
glenn1919 glenn1919 2 월 전
ctcx.......................weeeeeeeeeeeeeeeeeeeeeeeeee
👍️0
declaes declaes 2 월 전
The volume in the past few days was telling  I hope you all got in 🤑
👍️0
Invest-in-America Invest-in-America 2 월 전
CTCX: Bust that damn DOLLAR!!!
👍️0
Invest-in-America Invest-in-America 2 월 전
CTCX: Kick that ASK!!!!!
👍️0
Invest-in-America Invest-in-America 2 월 전
CTCX: My E-Turd gave me BIG problems, simply tryin' to grab this rocket ship today!! I DID get a decent price, but COULD have grabbed it like an insider at the PR firm just before they launched the NEWS!!! (I know, that's illegal --- but I wish I was only age 21 right now, & workin' at "GlobeNewswire" PR desk, for example!!! E.g., "Hello, MOM, grab a bunch of CTCX for us right now!!! I'm gonna tap the PR launch button in circa 10-minutes!!!")
👍️0
tw0122 tw0122 2 월 전
Yes acquiring $ELAB $2.41 assets .72 +'156% 
👍️0
Invest-in-America Invest-in-America 2 월 전
CTCX: Good news!!
👍️0
glenn1919 glenn1919 2 월 전
CTCX...............https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 월 전
8 million shares priced at .23 for commercial launch 
👍️0
tw0122 tw0122 2 월 전
1.8 private placemt and up it goes .47 + 110%
👍️0
glenn1919 glenn1919 3 월 전
ctcx......https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 월 전
CTCX, new 52 week low
👍️0
glenn1919 glenn1919 5 월 전
CTCX..............................https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 5 월 전
.56 + 16% Run run another pump whoops might be too late lol
👍️0
Invest-in-America Invest-in-America 5 월 전
CTCX: And STILL under $2.00.

_____________________________________________________________________
I'm producing a film, "American Cars of 1908" --- tap link below for latest edition:
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExOXVyb2N1NXVkejE5em04cDMyYnRvbDV2ejAzeHdsdmZzc2JxajQwZSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/f1NTdkdbG4XzW/giphy.gif
👍️0
glenn1919 glenn1919 5 월 전
CTCX...................................https://stockcharts.com/h-sc/ui?s=CTCX&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 5 월 전
Oh cmon
👍️0
frans frans 5 월 전
CTCX 0.53 X 0.53
👍️0
tw0122 tw0122 5 월 전
Ok .50 now
👍️0
Monksdream Monksdream 8 월 전
CTCX under $2
👍️0
Monksdream Monksdream 8 월 전
CTCX under $2
👍️0
stock1ace1 stock1ace1 2 년 전
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

https://www.businesswire.com/news/home/20230809916251/en/Carmell-Announces-Successful-Closing-of-Merger-with-Axolotl-Biologix-and-Launch-of-a-New-Brand-Identity
👍️0
stock1ace1 stock1ace1 2 년 전
CTCX $2.90 #merger complete rsi 22 oversold macd crossover bullish

https://stockcharts.com/h-sc/ui?s=Ctcx
👍️0
AJ Freely AJ Freely 2 년 전
$CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Up 57% Pre-Market/ Current Price $4.74
👍️0
Monksdream Monksdream 2 년 전
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
👍️0

최근 히스토리

NASDAQ
CTCX
Carmell
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지